Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape.
chicken embryo model
drug delivery
endosomal escape
mesoporous silica nanoparticles
redox-responsive
self-immolative
stimuli-responsive
targeting
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
03 Mar 2021
03 Mar 2021
Historique:
pubmed:
18
2
2021
medline:
27
7
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
The several biological barriers that nanoparticles might encounter when administered to a patient constitute the major bottleneck of nanoparticle-mediated tumor drug delivery, preventing their successful translation into the clinic and reducing their therapeutic profile. In this work, mesoporous silica nanoparticles have been employed as a platform to engineer a versatile nanomedicine able to address such barriers, achieving (a) excessive premature drug release control, (b) accumulation in tumor tissues, (c) selective internalization in tumoral cells, and (d) endosomal escape. The nanoparticles have been decorated with a self-immolative redox-responsive linker to prevent excessive premature release, to which a versatile and polyvalent peptide that is able to recognize tumoral cells and induce the delivery of the nanoparticles to the cytoplasm via endosomal escape has been grafted. The excellent biological performance of the carrier has been demonstrated using 2D and 3D
Identifiants
pubmed: 33596035
doi: 10.1021/acsami.0c21507
pmc: PMC7944478
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Silicon Dioxide
7631-86-9
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9656-9666Références
Small. 2010 Sep 20;6(18):1952-67
pubmed: 20690133
J Am Chem Soc. 2011 Feb 9;133(5):1534-44
pubmed: 21207964
Biochim Biophys Acta. 1997 Apr 26;1325(2):143-54
pubmed: 9168140
Sci Rep. 2018 Jun 4;8(1):8524
pubmed: 29867159
J Control Release. 2015 May 28;206:67-74
pubmed: 25770398
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Adv Mater. 2014 Apr 16;26(15):2398-402
pubmed: 24375889
Nanoscale Res Lett. 2018 Oct 25;13(1):339
pubmed: 30361809
Pharmaceutics. 2020 Jan 20;12(1):
pubmed: 31968690
J Mass Spectrom. 2009 Jan;44(1):81-9
pubmed: 18698560
Sci Rep. 2017 May 23;7(1):2274
pubmed: 28536462
Nanoscale. 2013 Nov 21;5(22):11153-65
pubmed: 24077327
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
J Nanobiotechnology. 2018 Sep 22;16(1):74
pubmed: 30243297
Pharm Res. 2018 Feb 14;35(3):63
pubmed: 29450652
Biomater Sci. 2015 Jul;3(7):1085-95
pubmed: 26221942
ACS Nano. 2019 Jul 23;13(7):7370-7376
pubmed: 31240914
J Control Release. 2017 Jan 28;246:110-119
pubmed: 28017891
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Expert Opin Drug Deliv. 2015 Feb;12(2):319-37
pubmed: 25421898
Br J Pharmacol. 2009 May;157(2):166-78
pubmed: 19459843
ACS Appl Mater Interfaces. 2020 Apr 1;12(13):14946-14957
pubmed: 32141284
Acc Chem Res. 2015 May 19;48(5):1380-90
pubmed: 25853734
ChemMedChem. 2020 Apr 3;15(7):593-599
pubmed: 32020745
Mol Pharm. 2017 May 1;14(5):1395-1404
pubmed: 28134535
Chem Commun (Camb). 2015 Jul 4;51(52):10403-18
pubmed: 26021457
Angew Chem Int Ed Engl. 2016 Oct 10;55(42):13023-13027
pubmed: 27666951
Chemistry. 2016 Sep 26;22(40):14126-30
pubmed: 27304830
Dalton Trans. 2016 Nov 15;45(45):18147-18155
pubmed: 27785492
J Virol. 2009 Feb;83(4):1727-41
pubmed: 19052089
Biochemistry. 1984 Sep 11;23(19):4409-16
pubmed: 6487609
Nat Nanotechnol. 2011 Nov 06;7(1):62-8
pubmed: 22056728
J Drug Target. 2015 Jun;23(5):469-79
pubmed: 25673266
Bioconjug Chem. 2019 Feb 20;30(2):263-272
pubmed: 30452233
Small. 2010 Aug 16;6(16):1794-805
pubmed: 20623530
Nanoscale. 2015 May 7;7(17):7953-64
pubmed: 25865957
Nanoscale. 2014 Jul 7;6(13):7436-42
pubmed: 24882040
Int J Nanomedicine. 2017 Apr 19;12:3221-3234
pubmed: 28458542
J Mater Chem B. 2018 May 14;6(18):2785-2794
pubmed: 32254231
Artif Cells Nanomed Biotechnol. 2018;46(sup1):578-587
pubmed: 29374971
Nanomaterials (Basel). 2020 May 09;10(5):
pubmed: 32397449
J Org Chem. 2013 Apr 5;78(7):3159-69
pubmed: 23414397
Macromol Rapid Commun. 2018 Jun;39(12):e1800071
pubmed: 29748982
Oxid Med Cell Longev. 2013;2013:972913
pubmed: 23766865
Cells. 2019 May 10;8(5):
pubmed: 31083409
J Am Chem Soc. 2014 May 21;136(20):7492-7
pubmed: 24786176
J Am Chem Soc. 2016 Aug 31;138(34):10834-7
pubmed: 27522867
Bioengineering (Basel). 2017 Jan 18;4(1):
pubmed: 28952481
Biochim Biophys Acta. 2001 Nov 1;1515(1):23-37
pubmed: 11597349
Nanoscale. 2018 Jan 18;10(3):1494-1507
pubmed: 29303184
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5):
pubmed: 28160452
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Am Chem Soc. 2008 Apr 23;130(16):5434-5
pubmed: 18376834
Nano Lett. 2020 May 13;20(5):4014-4021
pubmed: 32298126
Biomater Sci. 2013 Feb 3;1(2):114-134
pubmed: 32481793